Dr. Gudas is Chair and Revlon Pharmaceutical Professor of Pharmacology and Toxicology of the Pharmacology Department. She is a member of the American Society for Pharmacology and Experimental Therapeutics, the major organization of scientists doing research in pharmacology. She has served a term as an elected member of the Board of Directors of the American Association of Cancer Research, the largest organization of cancer researchers in the United States. Dr. Gudas also served a term as chair of the Board of Scientific Counselors of the National Institute of Diabetes and Digestive and Kidney Disorders. She chaired the Board of Scientific Counselors of the National Heart, Lung and Blood Institute as well. She has served as a member of the external advisory boards of three Cancer Centers: The Vermont Cancer Center, The Lineberger Cancer Center of U.N.C. Chapel Hill, and the University of Maryland Greenebaum Cancer Center. Of note, in 1999, she received the 2nd Annual "Women in Cancer Research" award from the American Association of Cancer Research. She has been on the Editorial Boards of a number of journals, including Molecular Cancer Therapeutics, Molecular and Cellular Biology, Molecular Cancer Research, Cancer Prevention Research, and the Journal of Biological Chemistry. In 2008 Dr. Gudas was elected to be a Fellow of the America Association for the Advancement of Science, and she recently received the 2013 Future of Health Technology Award for her cancer research. She served on an FDA Advisory Committee from 2013-2016. She is currently on the editorial board of the Annual Reviews of Pharmacology and Toxicology.
Dr. Gudas has had a long-standing research interest in vitamin A and its derivatives and metabolites, a group of compounds called retinoids. She and her laboratory members have studied the pharmacology and molecular actions of retinoids with respect to cancer treatment and cancer prevention for many years, during which time her research has been continuously supported by NIH and other agencies. Dr. Gudas’ research team is also focused on the molecular, epigenetic mechanisms by which stem cells differentiate, since differentiation is often aberrant or blocked in cancer cells. Her laboratory has developed new murine models for head and neck cancer, and for kidney cancer. The Gudas lab also now has a new focus on developing new drugs for diabetes, fatty liver disease, and diabetic nephropathy. Dr. Gudas, with fellow faculty members, Drs. Tang and Wagner, recently started a biotech company, Sveikatal, Inc.
"I've been chair of the Pharmacology Department at Weill Cornell for about 28 years. It's a wonderful job in a terrific department with smart, collegial, and interactive faculty, motivated students, and great postdoctoral fellows and technicians. My lab research team is so talented and enthusiastic about our research projects.”
To read more about current lab members, Click here.
When we're not working, check out what our lab does for fun!